STAT5 activation induced by diabetic LDL depends on LDL glycation and occurs via src kinase activity

Diabetes

Volumn 51, Issue 11, 2002, Pages 3311-3317

  Brizzi, Maria Felice ^a   Dentelli, Patrizia ^a   Gambino, Roberto ^a   Cabodi, Sara ^b   Cassader, Maurizio ^a   Castelli, Ada ^a   Defilippi, Paola ^b   Pegoraro, Luigi ^a   Pagano, Gianfranco ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; JANUS KINASE; LOW DENSITY LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P21; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STAT5 PROTEIN;

ADULT; AGED; ARTICLE; CASE REPORT; COMPLEX FORMATION; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVITY; FIBROBLAST; GENE EXPRESSION; GLYCATION; HUMAN; HUMAN CELL; LIPOPROTEIN METABOLISM; PRIORITY JOURNAL; PROTEIN INDUCTION;

EID: 0036829918     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.51.11.3311     Document Type: Article

References (38)

1. Ross R: The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362:801-809, 1993
2. King GL, Brownlee M: The cellular and molecular mechanisms of diabetic complications. Endocrinol Metab Clin North Am 25:255-270, 1996
3. Penn MS, Chisolm GM: Oxidized lipoproteins, altered cell function and atherosclerosis. Atherosclerosis 108 (Suppl.):S21-S29, 1994
4. Lyons TJ, Jenldns AJ: Lipoprotein glycation and its metabolic consequences. Curr Opin Lipidol 8:174-180, 1997
5. Howard BV: Lipoprotein metabolism in diabetes. Curr Opin Lipidol 5:216-220, 1994
6. Schmidt AM, Stern DM: RAGE: A new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Trends Endocrinol Metab 11:368-375, 2000
7. Palinski W, Koschinsky T, Butler SW, Miller E, Vlassara H, Cerami A, Witztum JL: Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. Arterioscler Thromb Vasc Biol 15:571-.582, 1995
8. Guh JY, Huang JS, Chen HC, Hung WC, Lai YH, Chuang LY: Advanced glycation end product-induced proliferation in NRK-49F cells is dependent on the JAK2/STAT5 pathway and cyclin D1. Am J Kidney Dis 38:1096-1104, 2001
9. Ihle JN, Kerr IM: Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet 11:69-74, 1995
10. Reddy EP, Korapati A, Chaturvedi P, Rane S: IL-3 signaling and the role of Src kinases, JAKs and STATs: A covert liaison unveiled. Oncogene 19:2532-2547, 2000
11. Mui AL, Wakao H, Kinoshita T, Kitamura T, Miyajima A: Suppression of interleukin-3-induced gene expression by a C-terminal truncated Stat5: Role of Stat5 in proliferation. EMBO J 15:2425-2433, 1996
12. Levy DE, Gilliland DG: Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruption in mice. Oncogene 19:2505-2510, 2000
13. Brizzi MF, Dentelli P, Pavan M, Rosso A, Gambino R, Grazia De Cesaris M, Garbarino G, Camussi G, Pagano G, Pegoraro L: Diabetic LDL inhibits cell-cycle progression via STAT5B and p2l(waf). J Clin Invest 109:111-119, 2002
14. Redgrave TG, Carlson LA: Changes in plasma very low density and low density lipoprotein content, composition, and size after a fatty meal in normo- and hypertriglyceridemic man. J Lipid Res 20:217-229, 1979
15. Stocks J, Nanjee MN, Miller NE: Analysis of high density lipoprotein apolipoproteins by capillary zone and capillary SDS gel electrophoresis. J Lipid Res 39:218-227, 1998
16. Stocks J, Miller NE: Capillary electrophoresis to monitor the oxidative modification of low density lipoproteins. J Lipid Res 39:1305-1309, 1998
17. Makino K, Furbee JW Jr., Scanu AM, Fless GM: Effect of glycation on the properties of lipoprotein(a). Arterioscler Thromb Vasc Biol 15;385-391, 1995
18. Brizzi MF, Garbarino G, Rossi PR, Pagliardi GL, Arduino C, Avanzi GC, Pegoraro L: Interleukin 3 stimulates proliferation and triggers endothelial-leukocyte adhesion molecule 1 gene activation of human endothelial cells. J Clin Invest 91:2887-2892, 1993
19. Soriano P, Montgomery C, Geske R, Bradley A: Target disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64:693-702, 1991
20. Brizzi MF, Dentelli P, Rosso A, Yarden Y, Pegoraro L: STAT protein recruitment and activation in c-Kit deletion mutants. J Biol Chem 274: 16965-16972, 1999
21. Sadowski HB, Gilman MZ: Cell-free activation of a DNA-binding protein by epidermal growth factor. Nature 362:79-83, 1993
22. Wakao H, Gouilleux F, Groner B: Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response. EMBO J 13:2182-2191, 1994
23. Calautti E, Missero C, Stein PL, Ezzell RM, Dotto GP: Fyn tyrosine kinase is involved in keratinocyte differentiation control. Genes Dev 9:2279-2291, 1995
24. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM: Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 272:17810-17814, 1997
25. cip1/waf1 undergo normal development, but are defective in G1 checkpoint control. Cell 82:675-684, 1995
26. Okutani Y, Kitanaka A, Tanaka T, Kamano H, Ohnishi H, Kubota Y, Ishida T, Takahara J: Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway. Oncogene 20:6643-6650, 2001
27. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D: Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 96:1395-1403, 1995
28. Raj DS, Choudhury D, Welbourne TC, Levi M: Advanced glycation end products: A Nephrologist's perspective. Am J Kidney Dis 35:365-380, 2000
29. Stitt AW, Bucala R, Vlassara H: Atherogenesis and advanced glycation: Promotion, progression, and prevention. Ann N Y Acad Sci 811:115-127 (discussion 127-129), 1997
30. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A: Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267:14998-15004, 1992
31. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, Esposito C, Hegarty H, Hurley W, Clauss M: Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 267:14987-14997, 1992
32. Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, Hofmann M, Yan SF, Pischetsrieder M, Stern D, Schmidt AM: N(epsilon)-(carboxymethyl) lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274:31740-31749, 1999
33. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stem D, Schmidt AM: RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. Cell 97:889-901, 1999
34. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D: Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269:9889-9897, 1994
35. Huttunen HJ, Fages C, Rauvala H: Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 274:19919-19924, 1999
36. Chaturvedi P, Reddy MV, Reddy EP: Src kinases and not JAKs activate STATs during IL-3 induced myeloid cell proliferation. Oncogene 16:1749-1758, 1998
37. Olayioye MA, Beuvink I, Horsch K, Daly JM, Hynes NE: ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J Biol Chem 274: 17209-17218, 1999
38. Freedman BI, Wuerth JP, Cartwright K, Bain RP, Dippe S, Hershon K, Mooradian AD, Spinowitz BS: Design and baseline characteristics for the Ammoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials 20:493-510, 1999